CN114191379A - Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method - Google Patents
Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method Download PDFInfo
- Publication number
- CN114191379A CN114191379A CN202111548839.5A CN202111548839A CN114191379A CN 114191379 A CN114191379 A CN 114191379A CN 202111548839 A CN202111548839 A CN 202111548839A CN 114191379 A CN114191379 A CN 114191379A
- Authority
- CN
- China
- Prior art keywords
- pluronic
- medicine
- gene
- transgenosis
- local
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001992 poloxamer 407 Polymers 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000028990 Skin injury Diseases 0.000 title claims abstract description 10
- 229940079593 drug Drugs 0.000 title claims abstract description 10
- 238000001727 in vivo Methods 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000012096 transfection reagent Substances 0.000 claims abstract description 10
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 3
- 238000005303 weighing Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 17
- 208000027418 Wounds and injury Diseases 0.000 abstract description 17
- 238000012637 gene transfection Methods 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 7
- 238000001890 transfection Methods 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 4
- 230000000717 retained effect Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 5
- 206010072170 Skin wound Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine for repairing skin injury by using Pluronic F127 as a vector to perform local transgenosis in vivo and a preparation method thereof. The preparation method of the medicine comprises the following steps: weighing Pluronic F127 particles, dissolving in 0.9% physiological saline to obtain 30 wt% Pluronic F127, and storing at 4 ℃; the gene to be transfected and the transfection reagent or drug are added to the Pluronic F127 solution prepared in step S1, mixed well, and the mixture is drawn into a syringe at 4 ℃ and stored at 4 ℃. The Pluronic F127 and the gene-transfection reagent/medicine mixture are liquid at 4 ℃, are converted into a gel state along with the temperature rise after being smeared on the skin, can be retained at the wound surface of the skin, realizes the slow release of the transfection gene or medicine, improves the local gene transfection efficiency and the medicine absorption, and promotes the wound surface healing.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a drug for repairing skin injury by using Pluronic F127 as a vector to perform local transgenosis in vivo and a preparation method thereof.
Background
When the skin is damaged or the chronic wound surface which is difficult to heal, such as diabetes, and the like needs to be treated for a long time, the genes which are helpful to promote the healing of the wound surface through transfection or medicines which are topically applied are helpful to the healing and the repair of the wound surface. However, systemic gene transfection by intravenous injection presents a series of problems: firstly, potential safety hazards exist, secondly, the efficiency is low, and thirdly, a large dosage is needed. Therefore, the inventor thinks that it is very necessary to provide a drug which is retained at the skin wound, realizes the slow release effect of the transfected gene, improves the local gene transfection efficiency and achieves the effect of promoting the wound healing.
Disclosure of Invention
In order to solve the technical problems, the invention provides a medicine for repairing skin injury by using Pluronic F127 as a vector to perform local transgenosis and a preparation method thereof.
The invention is realized by the following technical scheme.
A medicine for repairing skin injury by in-vivo local transgenosis with Pluronic F127 as a vector comprises Pluronic F127 and a transfected gene, reagent or medicine.
Preferably, the working concentration of Pluronic F127 is 25 wt%.
A preparation method of the medicine for repairing skin injury by using Pluronic F127 as a vector to perform local transgenosis in vivo comprises the following steps:
s1, weighing Pluronic F127 particles, dissolving the Pluronic F127 particles in 0.9% physiological saline to prepare 30 wt% Pluronic F127, and storing the Pluronic F127 at 4 ℃;
s2, adding the gene to be transfected and a transfection reagent or a medicament into the Pluronic F127 solution prepared in the step S1, fully and uniformly mixing, sucking the mixture into an injector at 4 ℃, and storing at 4 ℃ for later use.
The present application has the following advantageous effects.
According to the invention, 30% of Pluronic F127 is prepared as a slow release material, a gene to be transfected and a transfection reagent or a medicine are prepared in advance and are uniformly mixed with the Pluronic F127 in proportion, when the composition is placed at 4 ℃, the Pluronic F127 and a gene-transfection reagent/medicine mixture are liquid, and the mixture is converted into a gel state along with the temperature rise after being smeared on the skin, so that the gel state can be retained at the skin wound surface, the slow release of the transfection gene or the medicine is realized, the local gene transfection efficiency and the medicine absorption are improved, and the effect of promoting the wound surface healing is achieved.
Drawings
FIG. 1 is an image of a mouse live body 3 days after transfection in accordance with the present invention.
Detailed Description
The invention is further described below with reference to the figures and examples.
Example 1
A method for preparing a medicine for repairing skin injury by in-vivo local transgenosis by taking Pluronic F127 as a vector comprises the following steps:
s1, 9g of Pluronic F127 granules are weighed and dissolved in 0.9% physiological saline, stirred overnight at low temperature to prepare 30% Pluronic F127, and placed at 4 ℃ when the 30% Pluronic F127 is in liquid state.
S2, adding the gene to be transfected and a transfection reagent (PEI) into 50 mu L of 30% Pluronic F127 according to the proportion of 3 mu g to 2 mu L, adding a proper volume of 0.9% physiological saline to make up to 60 mu L, enabling the final concentration of the Pluronic F127 to be 25%, fully mixing, storing at 4 ℃, sucking the mixture into a 1mL syringe in a liquid state, and storing at 4 ℃ for later use.
Comparative example 1
The gene to be transfected and the transfection reagent (PEI) were dispensed in a suitable volume of 0.9% saline at a ratio of 3. mu.g: 2. mu.L to a final volume of 60. mu.L, mixed well, and then aspirated into a 1mL syringe, and stored at 4 ℃ for further use.
Animal experiments
2 full-skin-layer defective wound surfaces with the diameter of 6mm are symmetrically manufactured on the back of a mouse, a 1mL injector (with a needle removed) is adopted to inject a mixture to the local part of a skin wound surface in an experimental group (example 1), 60 mu L of the mixture is injected to each wound surface, the wound surface is uniformly coated, the temperature rises along with the coating, the Pluronic F127-gene-transfection reagent mixture is changed into a hydrogel state from a liquid state, vaseline gauze strips are covered, and the wound surfaces are fixed by self-adhesive bandages; the control group (comparative example 1) was injected with 60. mu.L of 0.9% physiological saline-gene-transfection reagent mixture liquid, adhered with a medical air-permeable tape, covered with a gauze strip of vaseline to prevent the loss of the mixture liquid as much as possible, and fixed with a self-adhesive bandage. Each mouse was individually bred, observed 3 days, 5 days and 7 days after the experiment, and subjected to in vivo imaging detection, and the local transfection effect of the gene on the wound surface was evaluated by fluorescence intensity. The results of the experiment are shown in FIG. 1.
As shown in FIG. 1, the control group was subjected to wound surface local gene transfection using 0.9% physiological saline as a medium, and the F127 group was subjected to wound surface local gene transfection using Pluronic F127 at a concentration of 25% as a medium. Local gene transfection is carried out after a mouse skin wound model is constructed, observation is carried out in a small animal living body imaging instrument after 3 days of transfection, and the local transfection gene condition can be reflected through the observed fluorescence intensity. The stronger the fluorescence, the higher the efficiency of the gene transfected locally. The result shows that F127 groups of wound surfaces all have fluorescence, and the fluorescence is very strong, which indicates that the carried gene is transfected into the wound surface tissue, while the control group of wound surfaces has no fluorescence, and the gene is not successfully transfected into the wound surface tissue.
The embodiments of the present invention are preferred embodiments of the present invention, and the scope of the present invention is not limited by these embodiments, so: all equivalent changes made according to the structure, shape and principle of the invention are covered by the protection scope of the invention.
Claims (3)
1. The drug for repairing the skin injury by using Pluronic F127 as a vector to perform local transgenosis is characterized in that: including Pluronic F127 and transfected genes, reagents or drugs.
2. The drug for repairing skin injury by using Pluronic F127 as a vector for local transgenosis in vivo according to claim 1, wherein: the working concentration of Pluronic F127 was 25 wt%.
3. A method for preparing a drug for repairing skin damage by in vivo local transgenosis with Pluronic F127 as a vector according to claim 1 or 2, which is characterized in that: the method comprises the following steps:
s1, weighing Pluronic F127 particles, dissolving the Pluronic F127 particles in 0.9% physiological saline to prepare 30 wt% Pluronic F127, and storing the Pluronic F127 at 4 ℃;
s2, adding the gene to be transfected and a transfection reagent or a medicament into the Pluronic F127 solution prepared in the step S1, fully and uniformly mixing, sucking the mixture into an injector at 4 ℃, and storing at 4 ℃ for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111548839.5A CN114191379A (en) | 2021-12-17 | 2021-12-17 | Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111548839.5A CN114191379A (en) | 2021-12-17 | 2021-12-17 | Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114191379A true CN114191379A (en) | 2022-03-18 |
Family
ID=80654798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111548839.5A Pending CN114191379A (en) | 2021-12-17 | 2021-12-17 | Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114191379A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024355A (en) * | 2022-06-09 | 2022-09-09 | 宁波大学科学技术学院 | Preparation method of allicin-based fresh-keeping coating for chilled fresh meat by composite carrier coating |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138636A (en) * | 2006-09-05 | 2008-03-12 | 中国科学院上海药物研究所 | Gene medicine conveying system and method of preparing the same |
| WO2011069587A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| US20150141498A1 (en) * | 2009-12-09 | 2015-05-21 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CN104826121A (en) * | 2015-02-11 | 2015-08-12 | 嘉兴学院 | Tumor targeted gene delivery system and application of same |
| CN111956668A (en) * | 2020-08-27 | 2020-11-20 | 北京瀚梅生物科技有限公司 | Skin regeneration and repair cell composition and preparation method thereof |
-
2021
- 2021-12-17 CN CN202111548839.5A patent/CN114191379A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101138636A (en) * | 2006-09-05 | 2008-03-12 | 中国科学院上海药物研究所 | Gene medicine conveying system and method of preparing the same |
| WO2011069587A1 (en) * | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Lyophilization of nucleic acids in lactate-containing solutions |
| US20150141498A1 (en) * | 2009-12-09 | 2015-05-21 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CN104826121A (en) * | 2015-02-11 | 2015-08-12 | 嘉兴学院 | Tumor targeted gene delivery system and application of same |
| CN111956668A (en) * | 2020-08-27 | 2020-11-20 | 北京瀚梅生物科技有限公司 | Skin regeneration and repair cell composition and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| DIANA RAFAEL: "Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized Pluronic® F127/Gelatin", 《CHEMICAL ENGINEERING JOURNAL》, vol. 340, pages 81 - 93, XP085357579, DOI: 10.1016/j.cej.2017.12.114 * |
| 陈云超: "不同浓度共聚物在保护超声介导细胞损伤和基因转染中的作用", 《化学与生物工程》, vol. 24, no. 8, pages 498 - 37 * |
| 陈云超: "共聚物在超声介导基因转染中的新功能", 《中华超声影像学杂志》, vol. 14, no. 11, pages 858 - 862 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024355A (en) * | 2022-06-09 | 2022-09-09 | 宁波大学科学技术学院 | Preparation method of allicin-based fresh-keeping coating for chilled fresh meat by composite carrier coating |
| CN115024355B (en) * | 2022-06-09 | 2023-06-09 | 宁波大学科学技术学院 | Preparation method of garlicin-based composite carrier coating for preserving chilled meat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Di et al. | Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules | |
| Zhang et al. | Microneedle system for tissue engineering and regenerative medicine | |
| DE69637198T2 (en) | REDOX AND PHOTOINITIATOR SYSTEM FOR PRESERVING IMPROVED ADHESION FROM GELS TO SUBSTRATES | |
| KR101881609B1 (en) | Microneedle assembly formulation for skin treatment | |
| CN111388407B (en) | Microneedle array based on dopamine gel and preparation and application thereof | |
| AU2017394923A1 (en) | Methods and systems for treating a site of a medical implant | |
| CN103289107A (en) | Preparation method and application of injectable silk fibroin in-situ gel | |
| CN108653198A (en) | It is a kind of can cutaneous penetration hydrogel and its preparation method and application | |
| CN110167624A (en) | Core-shell structure copolymer microneedle devices and application thereof | |
| CN107802887A (en) | A kind of temperature-sensitive hydrogel compound and its promotion are by the method and application of carrying cell survival and/or tissue repair | |
| KR20190102178A (en) | Microneedle Array with Chemicals | |
| CN108403663A (en) | GO-PEG gel micro-balls with nucleocapsid and its preparation method and application | |
| CN106474536A (en) | A kind of liquid bandage for War injury | |
| CN111870806A (en) | Magnetic control microneedle robot and preparation method, use method and application thereof | |
| CN114191379A (en) | Medicine for repairing skin injury by using Pluronic F127 as carrier to perform local transgenosis in vivo and preparation method | |
| CN103083224A (en) | Method for preparing dexamethasone slow-release medicine carrier | |
| CN114848577A (en) | Double-layer conductive microneedle patch for treating subcutaneous tumors and preparation method and application thereof | |
| CN103316351B (en) | A kind of electrostatic spinning compound of two kinds of medicines of loading | |
| Lin et al. | Biodegradable double-network GelMA-ACNM hydrogel microneedles for transdermal drug delivery | |
| CN109010922A (en) | Bone Defect Repari nano fibrous membrane and preparation method thereof | |
| CN116250840B (en) | Neural electrode assembly, preparation method thereof, implantation system and storage medium | |
| CN106176573B (en) | A kind of solubility hollow microneedles and preparation method thereof | |
| CN111281887A (en) | Thermo-sensitive hydrogel compound suitable for carrying human umbilical cord Wharton's jelly mesenchymal stem cells and application thereof | |
| CN115337255A (en) | Self-electrogenesis enzyme-linked microneedle patch and preparation method and application thereof | |
| CN110354102B (en) | Biphase transdermal drug delivery system and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220318 |